EA201790272A1 - Адресная доставка гидрофильных лекарственных средств - Google Patents

Адресная доставка гидрофильных лекарственных средств

Info

Publication number
EA201790272A1
EA201790272A1 EA201790272A EA201790272A EA201790272A1 EA 201790272 A1 EA201790272 A1 EA 201790272A1 EA 201790272 A EA201790272 A EA 201790272A EA 201790272 A EA201790272 A EA 201790272A EA 201790272 A1 EA201790272 A1 EA 201790272A1
Authority
EA
Eurasian Patent Office
Prior art keywords
aqueous
particles
methods
pharmaceutical composition
hydrophilic
Prior art date
Application number
EA201790272A
Other languages
English (en)
Other versions
EA033526B1 (ru
Inventor
Игорь Локот
Original Assignee
Дабл Бонд Фармасьютикалз Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дабл Бонд Фармасьютикалз Аб filed Critical Дабл Бонд Фармасьютикалз Аб
Publication of EA201790272A1 publication Critical patent/EA201790272A1/ru
Publication of EA033526B1 publication Critical patent/EA033526B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Фармацевтическая композиция в форме водного коллоидного раствора или водной суспензии частиц размером до 100 мкм, которая содержит или состоит из амфифильного сульфоната или сульфата гидрофильного противоопухолевого лекарственного средства, растворимость которой в воде или водной жидкости организма менее 0,1 мас.%. Также раскрыты частицы порошкообразной формы, способы их получения, способы получения коллоида и более грубой суспензии, способ лечения рака печени, в частности солидных раковых опухолей печени, путем введения фармацевтической композиции и способ разработки композиции по изобретению.
EA201790272A 2014-09-10 2015-09-09 Адресная доставка гидрофильных лекарственных средств EA033526B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1400427 2014-09-10
PCT/SE2015/000055 WO2016039678A1 (en) 2014-09-10 2015-09-09 Targeted delivery of hydrophilic drugs

Publications (2)

Publication Number Publication Date
EA201790272A1 true EA201790272A1 (ru) 2017-07-31
EA033526B1 EA033526B1 (ru) 2019-10-31

Family

ID=55459328

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790272A EA033526B1 (ru) 2014-09-10 2015-09-09 Адресная доставка гидрофильных лекарственных средств

Country Status (11)

Country Link
US (2) US10034838B2 (ru)
EP (1) EP3191138B1 (ru)
JP (1) JP6951971B2 (ru)
KR (1) KR20170054459A (ru)
CN (1) CN107073129B (ru)
AU (1) AU2015316252A1 (ru)
CA (1) CA2958820A1 (ru)
EA (1) EA033526B1 (ru)
IL (1) IL250637A0 (ru)
MX (1) MX2017003049A (ru)
WO (1) WO2016039678A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3426228A1 (en) * 2016-03-07 2019-01-16 Double Bond Pharmaceutical AB Targeted delivery of hydrophilic drugs to lung

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008599A1 (en) * 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
EP1073419A4 (en) * 1998-03-18 2009-03-25 Univ Technology Corp COMPOSITION, CONTAINING AMORPHOUS POLYMER, FOR DELAYED RELEASE.
US6613358B2 (en) * 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6384081B2 (en) * 1998-10-09 2002-05-07 Charles L. Berman Treatment of diseases of the eye characterized by the formation of metalloproteinase
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
ES2330326T3 (es) * 2002-05-24 2009-12-09 Angiotech International Ag Composiciones y metodos para recubrir implantes medicos.
US20040161466A1 (en) * 2003-02-14 2004-08-19 Biocompatibles Uk Limited Chemoembolisation
GB2415904B (en) * 2005-02-07 2006-10-25 Chiron Corp Preparing aldesleukin for pharmaceutical use
WO2009078756A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
CA2714514C (en) * 2008-02-08 2016-08-16 Qps Llc Non-polymeric compositions for controlled drug delivery
CN101327190B (zh) * 2008-07-29 2011-04-27 北京大学 一种供注射用的抗肿瘤长循环靶向脂质体
NZ606195A (en) * 2010-07-26 2015-02-27 Servier Lab Methods and compositions for liver cancer therapy
KR101728011B1 (ko) * 2013-01-23 2017-04-20 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 덱스트란 메타크릴레이트 및 생체적합성 음이온성 고분자를 포함하는 생분해성 마이크로 비드 및 이의 제조방법

Also Published As

Publication number Publication date
JP2017527593A (ja) 2017-09-21
EA033526B1 (ru) 2019-10-31
WO2016039678A1 (en) 2016-03-17
EP3191138A4 (en) 2018-06-20
AU2015316252A1 (en) 2017-03-09
CA2958820A1 (en) 2016-03-17
US10973772B2 (en) 2021-04-13
US20190046462A1 (en) 2019-02-14
US20170239192A1 (en) 2017-08-24
IL250637A0 (en) 2017-04-30
US10034838B2 (en) 2018-07-31
CN107073129B (zh) 2021-10-15
JP6951971B2 (ja) 2021-10-20
CN107073129A (zh) 2017-08-18
EP3191138C0 (en) 2024-05-29
EP3191138A1 (en) 2017-07-19
EP3191138B1 (en) 2024-05-29
MX2017003049A (es) 2017-05-23
KR20170054459A (ko) 2017-05-17

Similar Documents

Publication Publication Date Title
CL2016002308A1 (es) Nanopartículas que comprenden un ácido hidrofóbico, un copolímero de dibloque pla-peg o plga-peg, y 1 -4- 4-dimetilamino piperidin-1-il carbonilfenil-3-4-4,6-dimorfolin-4-il-1,3,5-triazin-2-ilfenilurea composición farmacética proceso de preparación y uso para tratar cáncer
CY1124546T1 (el) Υγρο σκευασμα για εισπνοη που περιεχει rpl554
MX2021007794A (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
BR112016022159B8 (pt) Pó e método para melhorar a aplicação tópica de um agente de benefício ácido
BR112016022607B8 (pt) Pó e método para aprimorar a aplicação tópica de minoxidil
WO2016161342A3 (en) Nitrobenzyl derivatives of anti-cancer agents
PH12019550088A1 (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
BR112017025631A2 (pt) composições oftálmicas aquosas, método de induzir ou aumentar a formação de lágrima, método de formação de aglomerados de ciclosporina a e uso de ciclosporina a
CL2017001605A1 (es) Composición farmacéutica que comprende plasminógeno y usos de este.
HRP20211177T1 (hr) Korteksolon 17alfa-valerat za uporabu u liječenju tumora
MX2018000637A (es) Nanocápsula para la administración de un compuesto lipófilo y proceso de preparación de la misma.
MX2019003988A (es) Formulaciones de nanoparticulas y sus metodos de fabricacion y uso.
NZ743320A (en) Method for preparing polymeric micelle containing anionic drug
CL2019002105A1 (es) Tratamiento de composiciones acuosas que incluyen finos.
WO2019090030A8 (en) Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201791537A1 (ru) Фармацевтическая композиция на основе наночастиц доцетаксела-альбумина, способ ее получения и ее применение
BR112018072768A2 (pt) suspensão, composição farmacêutica, método para formar uma suspensão fulvestrant aquosa, suspensão fulvestrant aquosa e método para tratar um indivíduo tendo câncer de mama
MX2018014576A (es) Nanopartículas para el suministro de fármaco y tratamientos para el cáncer resistente a fármacos.
CY1124893T1 (el) Φαρμακευτικο μeιγμα μαροπιταντης
MX2016012641A (es) Dispersiones solidas secas en aceite en agua por aspersion para inhalacion de ingredientes farmaceuticos activos.
MX2018011760A (es) Aducto de ciclodextrina-panobinostat.
EA201790272A1 (ru) Адресная доставка гидрофильных лекарственных средств
MX2017015202A (es) Formulaciones liquidas de celecoxib para administracion oral.
EP3450395A3 (en) Graphene oxide nanoparticle compositions and methods of making the same

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM